Novel Experimental COVID-19 Therapies Affecting Host Response

NCT04924660 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

1060

Enrollment

OTHER

Sponsor class

Conditions

COVID-19
SARS-CoV-2 Infection
Coronavirus Infection

Interventions

DRUG: TXA127
DRUG: TRV027
DRUG: Placebo
DRUG: Fostamatinib

Sponsor

Sean Collins

Collaborators

[object Object]
[object Object]